Related Experiment Video
Updated: May 20, 2026

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
Gene expression profiling to identify druggable targets in prion diseases
Federico Benetti1, Lisa Gasperini, Mattia Zampieri
1Laboratory of Prion Biology, Neurobiology Sector, Scuola Internazionale Superiore di Studi Avanzati-International School of Advanced Studies (SISSA-ISAS), Edificio Q1, Basovizza, Trieste, Italy.
Prion diseases remain challenging for drug discovery due to unknown molecular mechanisms. Transcriptome analysis offers insights into prion-induced changes, guiding future therapeutic strategies for neurodegeneration.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacogenomics
Background:
- Prion diseases present complex molecular mechanisms challenging drug discovery.
- High-throughput transcriptome analyses are emerging as a tool for identifying drug targets.
Purpose of the Study:
- To review transcriptional alterations in prion-infected biological systems.
- To discuss therapeutic strategies based on identified altered processes.
Main Methods:
- Overview of microarray analyses, including their advantages and limitations.
- Guidance for designing suitable microarray experiments for researchers.
Main Results:
- Detailed overview of transcriptional alterations induced by prion infection.
- Identification of altered biological processes relevant to prion diseases.
Conclusions:
- Current drugs targeting pathways from microarray analysis are ineffective for prion diseases.
- Integration of gene expression profiling, proteomics, and physiology is recommended for future research.
Related Concept Videos
Ribosome Profiling
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique helps...
Pharmacogenomics: Identification of New Drug Targets

